Biotech · Private company
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Track this companyFree. Adds Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- G305Phase 3 · Synovial SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- LV305Phase 3 · Synovial SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- atezolizumabPhase 2 · SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- CMB305Phase 2 · SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- G100Phase 1 · SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- ID-LV305Phase 1 · Melanoma - Currently EnrollingClinicalTrials.gov · fetched Nov 12, 2026
- Metronomic CPAPhase 1 · SarcomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2PHASE1 · TERMINATED · started Feb 18, 2020ClinicalTrials.gov NCT04222985 · fetched Nov 12, 2026
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)PHASE3 · TERMINATED · started Sep 18, 2018ClinicalTrials.gov NCT03520959 · fetched Nov 12, 2026
- Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)PHASE2 · TERMINATED · started Apr 29, 2015ClinicalTrials.gov NCT02609984 · fetched Nov 12, 2026
- Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1PHASE1 · TERMINATED · started Feb 28, 2015ClinicalTrials.gov NCT02387125 · fetched Nov 12, 2026
- Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1PHASE1 · COMPLETED · started May 30, 2014ClinicalTrials.gov NCT02122861 · fetched Nov 12, 2026